IRIS Accounts Production v24.3.2.46 11598297 Board of Directors 1.10.23 30.9.24 30.9.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh115982972023-09-30115982972024-09-30115982972023-10-012024-09-30115982972022-10-31115982972022-11-012023-09-30115982972023-09-3011598297ns15:EnglandWales2023-10-012024-09-3011598297ns14:PoundSterling2023-10-012024-09-3011598297ns10:Director12023-10-012024-09-3011598297ns10:PrivateLimitedCompanyLtd2023-10-012024-09-3011598297ns10:SmallEntities2023-10-012024-09-3011598297ns10:AuditExempt-NoAccountantsReport2023-10-012024-09-3011598297ns10:SmallCompaniesRegimeForDirectorsReport2023-10-012024-09-3011598297ns10:SmallCompaniesRegimeForAccounts2023-10-012024-09-3011598297ns10:FullAccounts2023-10-012024-09-3011598297ns10:Director22023-10-012024-09-3011598297ns10:Director42023-10-012024-09-3011598297ns10:Director52023-10-012024-09-3011598297ns10:Director62023-10-012024-09-3011598297ns10:RegisteredOffice2023-10-012024-09-3011598297ns5:CurrentFinancialInstruments2024-09-3011598297ns5:CurrentFinancialInstruments2023-09-3011598297ns5:Non-currentFinancialInstruments2024-09-3011598297ns5:Non-currentFinancialInstruments2023-09-3011598297ns5:ShareCapital2024-09-3011598297ns5:ShareCapital2023-09-3011598297ns5:SharePremium2024-09-3011598297ns5:SharePremium2023-09-3011598297ns5:RetainedEarningsAccumulatedLosses2024-09-3011598297ns5:RetainedEarningsAccumulatedLosses2023-09-3011598297ns5:PlantMachinery2023-10-012024-09-3011598297ns5:ComputerEquipment2023-10-012024-09-3011598297ns5:PlantMachinery2023-09-3011598297ns5:ComputerEquipment2023-09-3011598297ns5:PlantMachinery2024-09-3011598297ns5:ComputerEquipment2024-09-3011598297ns5:PlantMachinery2023-09-3011598297ns5:ComputerEquipment2023-09-3011598297ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-3011598297ns5:WithinOneYearns5:CurrentFinancialInstruments2023-09-301159829712023-10-012024-09-30
REGISTERED NUMBER: 11598297 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 September 2024

for

4D Medicine Limited

4D Medicine Limited (Registered number: 11598297)






Contents of the Financial Statements
for the Year Ended 30 September 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


4D Medicine Limited

Company Information
for the Year Ended 30 September 2024







DIRECTORS: Professor A Dove
P Smith
Dr P Reeves
Dr T Buckland
D Cowling





REGISTERED OFFICE: Room 134
D6 West Building Medicity
1 Thane Road
Nottingham
NG90 6BH





REGISTERED NUMBER: 11598297 (England and Wales)





ACCOUNTANTS: Kearney & Associates Limited
14 Harvey Road
Bedford
Bedfordshire
MK41 9LF

4D Medicine Limited (Registered number: 11598297)

Balance Sheet
30 September 2024

30.9.24 30.9.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 12,376 14,687

CURRENT ASSETS
Debtors 5 70,127 136,308
Cash at bank 1,662,930 359,053
1,733,057 495,361
CREDITORS
Amounts falling due within one year 6 79,325 132,725
NET CURRENT ASSETS 1,653,732 362,636
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,666,108

377,323

CREDITORS
Amounts falling due after more than
one year

7

-

740,000
NET ASSETS/(LIABILITIES) 1,666,108 (362,677 )

CAPITAL AND RESERVES
Called up share capital 9 14 9
Share premium 5,252,966 1,873,039
Retained earnings (3,586,872 ) (2,235,725 )
SHAREHOLDERS' FUNDS 1,666,108 (362,677 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

4D Medicine Limited (Registered number: 11598297)

Balance Sheet - continued
30 September 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 22 May 2025 and were signed on its behalf by:





P Smith - Director


4D Medicine Limited (Registered number: 11598297)

Notes to the Financial Statements
for the Year Ended 30 September 2024

1. STATUTORY INFORMATION

4D Medicine Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 50% on cost
Computer equipment - 50% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Revenue expenditure on research and development is written off in the year in which it is incurred. Capital expenditure in relation to research and development projects is depreciated over the shorter of the expected life of the asset or the project.

4D Medicine Limited (Registered number: 11598297)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

2. ACCOUNTING POLICIES - continued

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 12 (2023 - 9 ) .

4. TANGIBLE FIXED ASSETS
Plant and Computer
machinery equipment Totals
£    £    £   
COST
At 1 October 2023 225,748 13,191 238,939
Additions 11,759 - 11,759
At 30 September 2024 237,507 13,191 250,698
DEPRECIATION
At 1 October 2023 214,133 10,119 224,252
Charge for year 12,047 2,023 14,070
At 30 September 2024 226,180 12,142 238,322
NET BOOK VALUE
At 30 September 2024 11,327 1,049 12,376
At 30 September 2023 11,615 3,072 14,687

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.9.24 30.9.23
£    £   
Other debtors 1,024 66,323
VAT 22,577 22,710
Prepayments 46,526 47,275
70,127 136,308

4D Medicine Limited (Registered number: 11598297)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.9.24 30.9.23
£    £   
Trade creditors 44,438 109,841
Social security and other taxes 11,667 8,424
Accrued expenses 23,220 14,460
79,325 132,725

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN
ONE YEAR
30.9.24 30.9.23
£    £   
Other loans (see note 8) - 740,000

8. LOANS

An analysis of the maturity of loans is given below:

30.9.24 30.9.23
£    £   
Amounts falling due between one and two years:
Convertible loan notes - 740,000

The convertible loans converted to shares in the year as part of a larger issue.

The loans converted at a price equal to the price paid for the shares by other investors, subject to a 20 per cent discount.

4D Medicine Limited (Registered number: 11598297)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

9. CALLED UP SHARE CAPITAL

Allocated, issued and fully paid:
Number: Class: Nominal 30.09.24 31.09.23
£ £
48,729 Ordinary £0.0001 5 4
24,414 A Ordinary £0.0001 2 2
11,584 B Ordinary £0.0001 1 1
15,955 C Ordinary £0.0001 2 2
1 D Ordinary £0.0001 - -
33,143 E Ordinary £0.0001 3
7,183 F Ordinary £0.0001 1 -
14 9

Shares were issued during the year as follows:

Cash at par
4,386 Ordinary shares of £0.0001 for £0

Cash at premium
33,143 E Ordinary shares of £0.0001 for £2,737,793
7,183 F Ordinary shares of £0.0001 for £640,221












10. POST BALANCE SHEET EVENTS

In April 2025 the Company raised £538k (before expenses) through an issue of ordinary shares.

11. SHARE-BASED PAYMENT TRANSACTIONS

In 2020 the company implemented an equity-settled share-based payment plan.

The company has issued share options to staff and directors under this plan. Some of these options have subsequently been exercised.

The directors have considered recognising a charge in respect of share based payments. However the directors have agreed that any such charge is not material to the accounts and therefore it has not been included.